Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954841 | 0.81 | NPC1 (0.54) | NPC1RAB9AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL8761770 | 0.80 | MAPT (0.49) | NPC1RAB9AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL8819753 | 0.78 | VEGFA (0.42) | NPC1RAB9AMAPTL3MBTL1MAPK14 | |
| SCHEMBL8762055 | 0.78 | MAPK14 (0.41) | NPC1RAB9AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL18526976 | 0.77 | NPC1 (0.52) | NPC1RAB9AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL1841867 | 0.77 | L3MBTL1 (0.49) | NPC1RAB9AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL955846 | 0.76 | MAOB (0.54) | NPC1RAB9AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL698534 | 0.76 | MAPT (0.48) | NPC1RAB9AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL8761568 | 0.75 | L3MBTL1 (0.45) | NPC1RAB9AMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL8761806 | 0.75 | MAPT (0.47) | NPC1RAB9AMAPTL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791266-B2 | Thyroid hormone β receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8791266-B2 | Thyroid hormone β receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8791266-B2 | Thyroid hormone β receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8748620-B2 | — | — | 2014-06-10 | — | — | US | disclosed |
| US-8748620-B2 | — | — | 2014-06-10 | — | — | US | disclosed |
| US-8748620-B2 | — | — | 2014-06-10 | — | — | US | disclosed |
| EP-2423194-B1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-20120129812-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120129812-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120129812-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-24 | — | — | US | disclosed |
| EP-2423194-A1 | NOVEL THYROID HORMONE beta RECEPTOR AGONIST | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129812-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | THRB, TSHR, THRA | NPC1 2579/4885RAB9A 1368/4885MAPT 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.